Clinical Trial Detail

NCT ID NCT03033576
Title Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

melanoma

Therapies

Ipilimumab

Ipilimumab + Nivolumab

Age Groups:

No variant requirements are available.